Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.
The antisecretory effects of somatostatin (SRIH) and its analogs are widely recognized and provide the basis for treatment of hormonal hypersecretion in patients with pituitary adenomas, especially in the settings of acromegaly. Dopamine (DA) agonists have also been used for medical treatment of prolactin and/or GH hypersecretion, and recent evidence points to an even greater antisecretory effect for a chimeric molecule, having high affinity for both SRIH and DA receptors. Evidence for an antiproliferative effect of these compounds has also been provided. This review focuses on the antiproliferative effects of SRIH and its analogs, of DA and chimeric compounds on pituitary adenomas, and on the clinical consequences on tumor volume of pharmacological treatment of pituitary adenomas with these drugs.
Zatelli
Maria Chiara
MC
Ambrosio
Maria Rosaria
MR
Bondanelli
Marta
M
Uberti
Ettore C Degli
ECD
D000172:Acromegaly / Q000188:drug therapy / Q000209:etiology; D000236:Adenoma / Q000150:complications / Q000188:drug therapy*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D018491:Dopamine Agonists / Q000494:pharmacology*; D006801:Humans; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D017481:Receptors, Somatostatin / Q000187:drug effects; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000502:physiology
D018491:Dopamine Agonists; D011954:Receptors, Dopamine; D017481:Receptors, Somatostatin; D013004:Somatostatin